Overview
WW International Q3 revenue declined 10.8% yr/yr
Clinical Subscription Revenue grew 35% yr/yr, reflecting strong retention
Company narrows 2025 guidance to higher end for revenue and adjusted EBITDA
Outlook
Company narrows 2025 revenue guidance to $695 mln - $700 mln
Company narrows 2025 adjusted EBITDA guidance to $145 mln - $150 mln
Result Drivers
CLINICAL REVENUE GROWTH - Clinical Subscription Revenue increased 35% yr/yr due to strong retention of members using compounded semaglutide
DEBT REDUCTION - Co reduced total debt by over 70% post-restructuring, strengthening balance sheet
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | $172 mln |
Press Release: ID:nGNXbL53gc
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments